In 2007, Silence Therapeutics Plc chose its present name and recruited a new chief executive officer and a vice president for intellectual property in order to sharpen its focus on RNAi-based therapeutics. These are compounds made up of double-stranded fragments of RNA that can silence genes that lead to disease
